Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807636 · ClinicalTrials.gov registry record · Phase 3
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,213
- Enrollment target
NCT02807636: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT02807636 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,213 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807636, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,213 participants
- Enrollment target
Study Summary
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Primary Outcome
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- OTHER Placebo
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,213 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 3 |
What the finished NCT02807636 record still lists
NCT02807636 is an interventional study that assigns participants to a tested intervention. Its 1,213 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02807636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02807636 about?
NCT02807636 is a clinical study titled "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma". A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
What is the current status of trial NCT02807636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,213 participants. The study started on 2016-06-30. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT02807636?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Placebo (OTHER), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02807636?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02807636's enrollment target sits among peer trials
1,213 216th of 2000 higher than 1,785 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI